lymphoma.ca - Targeted Therapy

Targeted Therapy | Lymphoma Canada

Lymphoma.ca Spined HTML

Targeted Therapy | Lymphoma Canada Jump to navigation Lymphoma Canada Languages Français English Know Your Nodes Contact Us Donate Lymphoma Canada Main menuWell-nighUsOur TeamBoard of Directors Scientific Advisory Board Our Partners Annual Reports Contact Us LymphomaPatient ExperienceTaking ControlFinding Clinical Trials Your Healthcare Team Questions To Ask Your Healthcare Team Young Adults Coping with CancerCoping and Emotions TalkingWell-nighYour Cancer Exercise Nutrition Advocacy Advanced Planning Loss and Grief Advanced Cancer CaregiversBasics of Caregiving Caring for someone with Lymphoma Tips for Caregivers Self-care for Caregivers Caregivers Need from Healthcare Professionals Care for the Caregiver Advanced Cancer Caregivers OverviewCancer Lymphatic System Blood &UnorthodoxyMarrow Lymphoma CLL & SLLAbout CLL & SLLDevelopment of CLL How CLL Affects the Body Risks Signs & Symptoms Richter's Transformation DiagnosisLab Tests Staging Watch & Wait TreatmentOverview of CLL Treatment Options Chemotherapy Antibody Therapy Targeted Therapy Radiation Therapy Splenectomy StemLaminaTransplantation Supportive Care CLL ResourcesVideos Hodgkin LymphomaSigns & Symptoms DiagnosisSubtypes Staging Treatment Non-Hodgkin LymphomaSigns & Symptoms Causes TreatmentGoals of Treatment Watch and Wait Biologics Radiation SurgeryUnorthodoxyMarrow Transplant Complementary Therapies Side Effect Management Low Blood Counts Post Treatment Staging Classifying NHL Grading NHL NHL Subtypes TreatmentAggressive NHL Indolent NHL Get InvolvedWays to GiveMonthly Giving Planned GiftBequests Life Insurance Stocks Annuities Charitable Remainder Trust A Gift of Residual Interest ECHOage Volunteer Join an event Create an event Share your story Shared Stories News & EventsNewsImprovingWangleto Innovative Cancer Therapies Lien pour le sondage patients/proches LLA et LDGCB r/r Big News in Nova Scotia Events2018 National Patient Conference - Quebec City Vancouver Patient Conference - Sept 15 take it to the mat Toronto take it to the mat Montreal Programs & ResourcesPublications Educational Sessions Healthcare ProfessionalsResearch Fellowship SupportSupport Groups Peer Support Program Financial Assistance Helpful LinksGlossary Newsletter Archive Search form Search Search Main menuWell-nighUsOur TeamBoard of Directors Scientific Advisory Board Our Partners Annual Reports Contact Us LymphomaPatient ExperienceTaking ControlFinding Clinical Trials Your Healthcare Team Questions To Ask Your Healthcare Team Young Adults Coping with CancerCoping and Emotions TalkingWell-nighYour Cancer Exercise Nutrition Advocacy Advanced Planning Loss and Grief Advanced Cancer CaregiversBasics of Caregiving Caring for someone with Lymphoma Tips for Caregivers Self-care for Caregivers Caregivers Need from Healthcare Professionals Care for the Caregiver Advanced Cancer Caregivers OverviewCancer Lymphatic System Blood &UnorthodoxyMarrow Lymphoma CLL & SLLAbout CLL & SLLDevelopment of CLL How CLL Affects the Body Risks Signs & Symptoms Richter's Transformation DiagnosisLab Tests Staging Watch & Wait TreatmentOverview of CLL Treatment Options Chemotherapy Antibody Therapy Targeted Therapy Radiation Therapy Splenectomy StemLaminaTransplantation Supportive Care CLL ResourcesVideos Hodgkin LymphomaSigns & Symptoms DiagnosisSubtypes Staging Treatment Non-Hodgkin LymphomaSigns & Symptoms Causes TreatmentGoals of Treatment Watch and Wait Biologics Radiation SurgeryUnorthodoxyMarrow Transplant Complementary Therapies Side Effect Management Low Blood Counts Post Treatment Staging Classifying NHL Grading NHL NHL Subtypes TreatmentAggressive NHL Indolent NHL Get InvolvedWays to GiveMonthly Giving Planned GiftBequests Life Insurance Stocks Annuities Charitable Remainder Trust A Gift of Residual Interest ECHOage Volunteer Join an event Create an event Share your story Shared Stories News & EventsNewsImprovingWangleto Innovative Cancer Therapies Lien pour le sondage patients/proches LLA et LDGCB r/r Big News in Nova Scotia Events2018 National Patient Conference - Quebec City Vancouver Patient Conference - Sept 15 take it to the mat Toronto take it to the mat Montreal Programs & ResourcesPublications Educational Sessions Healthcare ProfessionalsResearch Fellowship SupportSupport Groups Peer Support Program Financial Assistance Helpful LinksGlossary Newsletter Archive Search form Search Search You are hereHome > Lymphoma > CLL & SLL > Treatment > Targeted Therapy Targeted Therapy Scientists are learning increasingly well-nigh the lamina signals (the liaison of information within the lamina and between cells) that contribute to the growth and survival of CLL and SLL cells. Drugs are stuff ripened to specifically woodcut these signals and stop the growth and spread of CLL and SLL cells, while limiting forfeiture to healthy cells. There are many new targeted therapies undergoing investigation in clinical trials and some have recently been tried to treat CLL. Many of these targeted therapies are misogynist in pill form, making it possible for patients to take their medication at home. Most targeted therapies stupefy the unorthodoxy marrow so there is a risk of infection and bleeding.  Many patients wits fatigue and the drugs can rationalization nausea or exenterate upset.  Some of these drugs can moreover rationalization peripheral neuropathy (see unravelment under chemotherapy side effects). Currently, the drugs ibrutinib, idelalisib and venetoclax are the only targeted therapies tried by Health Canada for the treatment of patients with CLL. Ibrutinib (Imbruvica®) Ibrutinib is a drug that attaches directly to a protein tabbed Bruton's tyrosine kinase (BTK), which is very zippy in CLL cells. BTK sends signals in the lamina to help it grow and survive. Ibrutinib blocks the signals from BTK, which helps stop or slow lanugo the semester and survival of CLL cells. Ibrutinib comes in pills (tablets) that must be taken every day. Ibrutinib has been tried by Health Canada for treatment of the pursuit patients with CLL: Previously untreated CLL with 17p deletion. Previously untreated CLL and not considered towardly for treatment with a fludarabine-based regimen. Those who have received at least one prior therapy and are not considered towardly for treatment or re-treatment with a fludarabine-based regimen (ibrutinib vacated or in combination with bendamustine and rituximab). Ibrutinib is currently reimbursed by some public and private drug insurance programs in Canada. Janssen offers a patient support program for those stuff treated with ibrutinib and, in some cases, for those who need assitance to wangle ibrutinib. You can find out increasingly here or you can email imbruvica@bioadvancemail.ca. Find information on potential side effects here. Idelalisib (Zydelig®) Idelalisib is a drug that blocks the signals from a protein tabbed phosphoinositide 3-kinase (PI3K)-delta. The main job of PI3K-delta is to send signals that help B lamina grow, divide and survive. By blocking the signal from PI3K-delta, idelalisib helps stop or slow lanugo the growth of CLL and SLL cells. Idelalisib comes in pills (tablets) that must be taken every day. Idelalisib has been tried by Health Canada for treatment of the pursuit patients with CLL: In combination with rituximab for those who have received at least one prior treatment. Idelalisib is currently reimbursed by some public and private drug insurance programs in Canada. For information well-nigh wangle to idelalisib, contact the Gilead Oncology Patient Support Program: 1-844-453-6777 Find information on potential side effects here. Venetoclax (Venclexta®) Venetoclax is a drug that attaches to a protein tabbed b-cell lymphoma 2 (Bcl-2). Bcl-2 plays an important role in keeping cells working by blocking the deportment of proteins that rationalization lamina death. By attaching to Bcl-2, venetoclax stops Bcl-2 from inhibiting lamina death. Venetoclax comes in pills (tablets) that must be taken every day. Venetoclax has been tried by Health Canada for treatment of the pursuit patients with CLL: Those with 17p deletion who have received at least one prior therapy. Those without 17p deletion who have received at least one prior therapy and for whom there are no other misogynist treatment options. Venetoclax is currently not reimbursed by public drug insurance programs in Canada, but is covered by some private insurance programs. For assistance with wangle to venetoclax, undeniability the Abbvie Care Program: 1-844-346-6626  Find information on potential side effects here. Lymphoma PatientWitsOverview CLL & SLLAbout CLL & SLL Diagnosis Watch & Wait TreatmentOverview of CLL Treatment Options Chemotherapy Antibody Therapy Targeted TherapySide Effects - Targeted Therapy Radiation Therapy Splenectomy StemLaminaTransplantation Supportive Care CLL Resources Hodgkin Lymphoma Non-Hodgkin Lymphoma Are you a patient? Get Informed Are you a healthcare professional? See Resources News & Events October 28, 2018 NewsTITTM NewsEvents 3rd Annual take it to the mat Montreal- Registration now open! Idolem Hot... Read increasingly well-nigh 3rd Annual take it to the mat Montreal- Registration now open! October 28, 2018 NewsTITTM NewsEvents 3rd Annual take it to the mat Montreal- Registration now open! Idolem Hot... Read increasingly well-nigh 3rd Annual take it to the mat Montreal- Registration now open! Main MenuWell-nighUsOur Team Our Partners Annual Reports Contact Us LymphomaPatientWitsOverview CLL & SLL Hodgkin Lymphoma Non-Hodgkin Lymphoma Get InvolvedWays to Give Volunteer Join an event Create an event Share your story Shared Stories News & EventsNews Events Programs & ResourcesPublications Educational Sessions Healthcare Professionals Support Helpful Links Newsletter Archive Social Media Facebook Twitter Google + YouTube Instagram LinkedIn Contact Us Lymphoma Canada 6860 Century Avenue, Suite 202 Mississauga, ON L5N 2W5Telephone 905.858.5967 Toll Free: 1.866.659.5556General inquiries: info@lymphoma.ca Donate With your support, no one will have to squatter lymphoma alone. You can make a difference! Donate Join Our Mailing List First name Last name Email write * Submit Lymphoma Canada Legal menu Donate Accessibility Privacy Policy Terms & Conditions Charitable Registration Number: 87346 1040 RR0001 All material copyright © 2018 Lymphoma Canada